Older Adults and Medical Cannabis: Promising Interest, Scarce Evidence

A 2019 narrative review published in Drugs & Aging finds that clinical evidence for medical cannabis efficacy in older adults is remarkably limited, drawn almost entirely from younger populations, and accompanied by meaningful age-specific safety concerns, while offering a pragmatic, opinion-based framework for individualized shared decision-making.

Why This Matters

Cannabis legalization is expanding rapidly worldwide, and older adults represent one of the fastest-growing segments of new cannabis users. This population faces a convergence of unmet therapeutic needs, particularly around chronic pain, sleep, and mood, alongside heightened pharmacological vulnerability due to polypharmacy, declining hepatic function, and reduced physiological reserves. Clinicians are fielding these patient conversations now, often without age-appropriate evidence to guide them. This review attempts to consolidate what is and is not known, making its limitations as instructive as its findings.

Clinical Summary

The endocannabinoid system, comprising CB1 and CB2 receptors distributed widely throughout the central nervous system and peripheral tissues, provides a biologically plausible rationale for cannabinoid-based therapeutics across conditions common in older adults, including chronic pain, insomnia, neurodegeneration, and cancer-related symptoms. Published in Drugs & Aging in 2019, this narrative review by a team of clinical experts synthesizes existing biological, pharmacological, and clinical literature to assess the state of evidence for medical cannabis use among patients aged 60 years and older. The mechanistic logic is coherent: cannabinoids modulate pain signaling, inflammation, sleep architecture, and mood through well-characterized receptor pathways. However, the authors are forthright that biological plausibility has not been translated into robust clinical evidence for this age group.

The review’s central finding is that efficacy evidence is “scanty” and that virtually all randomized trial participants in cannabinoid studies are younger than 60, making direct extrapolation to older adults scientifically unjustifiable. On the safety side, the authors detail age-specific risks including cognitive impairment, cardiovascular events, gait instability and falls, and drug interactions mediated through CYP450 hepatic metabolism, all of which are amplified by polypharmacy and reduced physiological reserve. Their proposed clinical framework, which centers on individualized benefit-risk assessment and shared decision-making, is explicitly pragmatic and opinion-based rather than derived from high-quality evidence synthesis. The authors call for dedicated clinical trials enrolling older adults before firm recommendations can be made.

Dr. Caplan’s Take

This review is valuable precisely because of its honesty. The authors do not overstate what we know, and they correctly identify the fundamental problem: we are making clinical decisions for older patients based on evidence generated in younger ones. Every week I see patients over 65 asking about cannabis for pain or sleep, often after reading a news story or hearing from a friend. What they deserve is a transparent conversation about how little direct evidence exists for their age group and how much more vulnerable they are to side effects than the populations actually studied.

In practice, I approach these conversations with a structured benefit-risk framework. For patients with refractory symptoms who have exhausted conventional options, I consider low-dose CBD-predominant formulations as a starting point, with careful monitoring for cognitive changes, balance issues, and drug interactions. I review their full medication list with particular attention to CYP450 substrates. I never frame cannabis as a proven therapy for this population, because it is not. What I can offer is a cautious, supervised trial with clear stopping rules and honest expectations.

Clinical Perspective

This review sits very early in the research arc for geriatric cannabinoid therapeutics. It confirms what many clinicians already suspect: that the enthusiasm surrounding medical cannabis has outpaced the evidence, particularly for the age group most likely to experience both chronic symptom burden and adverse drug effects. The review does not provide new data, and its narrative methodology means that potentially important studies, including those with negative or null findings, may have been excluded. Clinicians should treat its efficacy summaries as incomplete rather than definitive, and its clinical framework as expert opinion rather than guideline-level recommendation.

From a pharmacological standpoint, the CYP450 interaction profile of THC and CBD warrants serious attention in older patients. Both cannabinoids inhibit CYP3A4 and CYP2C19, with potential to alter levels of common geriatric medications including anticoagulants, statins, calcium channel blockers, and benzodiazepines. Cardiovascular risks, including orthostatic hypotension and tachycardia, are clinically relevant in patients with compromised hemodynamic regulation. The most actionable step a clinician can take today is to conduct a thorough medication reconciliation before any cannabinoid trial in an older patient, and to document an explicit shared decision-making conversation that acknowledges the absence of age-specific efficacy data.

Study at a Glance

Study Type

Narrative review with expert clinical recommendations

Population

Older adults (target); most cited evidence from participants aged under 60 years

Intervention

THC, CBD, pharmaceutical cannabinoids (nabilone, nabiximols), whole-plant cannabis

Comparator

Not applicable (review article)

Primary Outcomes

Efficacy across chronic pain, sleep, mood, neurological, and cancer-related symptoms; age-specific safety profile

Sample Size

Not applicable (narrative synthesis of existing literature)

Journal

Drugs & Aging, Volume 36, pages 39-51

Year

2019

DOI or PMID

DOI not provided in source; Drugs & Aging 2019;36:39-51

Funding Source

Not specified in available text

What Kind of Evidence Is This

This is a narrative review, which occupies a relatively low position in the evidence hierarchy compared to systematic reviews or meta-analyses. Unlike systematic reviews, narrative reviews do not employ a predefined, reproducible search strategy, meaning the selection of cited studies reflects the authors’ judgment rather than a comprehensive literature canvas. The single most important inference constraint this imposes is that the evidence base presented may be incomplete, and the resulting conclusions, particularly regarding efficacy, cannot be assumed to represent the full weight of available data.

How This Fits With the Broader Literature

This review aligns with the broader pattern in cannabinoid medicine research: a substantial body of preclinical and mechanistic work paired with a thin and methodologically uneven clinical trial literature. Systematic reviews such as the 2015 Whiting et al. analysis in JAMA reached similarly cautious conclusions about cannabinoid efficacy for most indications, though that review also did not stratify by age. The 2017 National Academies of Sciences report on cannabis therapeutics likewise noted moderate evidence for chronic pain and chemotherapy-induced nausea but acknowledged significant gaps for other indications and populations.

What this review contributes specifically is the explicit framing of age as a modifier of both efficacy generalizability and safety risk. This geriatric lens is largely absent from earlier syntheses and represents a meaningful, if preliminary, addition to the clinical conversation.

Common Misreadings

The most likely overinterpretation is to read the review’s pragmatic clinical framework as an endorsement of medical cannabis for older adults. The authors are careful to frame their guidance as opinion-based and contingent on shared decision-making, yet the very existence of a “how to prescribe” section can create a false impression that efficacy has been established and that the remaining question is merely one of dosing and monitoring. In reality, the review’s own evidence summary makes clear that efficacy in this population has not been demonstrated, and the proposed framework is a clinical stopgap, not a validated protocol.

Bottom Line

This narrative review usefully consolidates the biological rationale, limited clinical evidence, and age-specific safety concerns surrounding medical cannabis use in older adults. It does not establish efficacy for any indication in this population. Its clinical framework is expert opinion, not evidence-based guidance. For now, clinicians should approach cannabinoid use in older patients with transparent caution, thorough medication review, and honest acknowledgment that the evidence base has not caught up with patient demand.

References

1. van den Elsen GAH, Ahmed AIA, Lammers M, et al. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Research Reviews. 2014;14:56-64.
2. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473.
3. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
4. Abuhasira R, Schleider LBL, Mechoulam R, Novack V. Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine. 2018;49:44-50.
5. Brunt TM, van Genugten M,”; et al. Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. Journal of Clinical Psychopharmacology. 2014;34(3):344-349.